Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Clever Leaves Holdings Inc. (CLVR)
USD0.00
+0.00 (+0.00%)
US OTC Healthcare Drug Manufacturers - Specialty & Generic
Address
6501 Congress Avenue 33487
Boca Raton, FL, US
Boca Raton, FL, US
CEO
Andres Fajardo
Website
cleverleaves.com
IPO
2020-12-18
CIK 1819615 ISIN CA1867602031
Also trades on
NASDAQ Capital Market · CLVRW (USD)
Other OTC · CLVR (USD)
Description
Clever Leaves Holdings Inc. is a company primarily focused on the cannabis sector. Its operations are structured into two distinct divisions: Cannabinoid and Non-Cannabinoid. The Cannabinoid segment oversees the global cultivation, extraction, manufacturing, commercialization, and distribution of cannabinoid-based products. In contrast, the Non-Cannabinoid segment, operating within the United States, specializes in the formulation, production, marketing, sales, and delivery of a diverse array of nutraceuticals, natural remedies, wellness items, detoxification solutions, and various nutritional and dietary supplements. These products are supplied to a broad clientele, including mass retailers, specialized health stores, and distributors. The company was founded in 2017 and is headquartered in Boca Raton, Florida.
Market Cap & Enterprise Value
Merger & Acquisition History
| Target company | Ticker | Date | Filing |
|---|---|---|---|
| Schultze Special Purpose Acquisition Corp. II | SAMA | 2020-08-06 | View |
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.00
+0.00 (+0.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
34
Beta
4.48
Float Shares
1.43M
Free Float %
81.6%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | +100.00% | -96.80% | +300.00% | +100.00% | -99.99% | -100.00% | -100.00% | -100.00% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (2 ratings, all time)
Buy
Price Targets & DCF
Current price
0.00
Ratings Trend (MoM)
0% Bullish
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-10.11
Distress
Piotroski F-Score
3 / 9
Average
MOAT Score
1 / 10
No MOAT
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+6.1% Q4'23: +0.5% (vs Q4'22)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+77.9% ★ Q4'23: +85.1% (vs Q4'22)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-96.7% Q4'23: -29.9% (vs Q4'22)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%-113.0% Q4'23: -108.3% (vs Q4'22)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%-101.1% Q4'23: -103.2% (vs Q4'22)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+22.5% Q4'23: +18.7% (vs Q4'22)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×-0.12× Q4'23: -0.11× (vs Q4'22)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
|---|---|---|---|---|---|
| Revenue |
15.37M
est: 15.32M (+0.4%)
|
16.41M
est: 17.30M (-5.1%)
|
17.42M
est: 20.00M (-12.9%)
|
30.00M
est.
|
104.80M
est.
|
| EBITDA |
-34.36M
est: -15.22M (-125.8%)
|
-37.75M
est: -17.18M (-119.7%)
|
-16.84M
est: -19.87M (+15.3%)
|
-29.80M
est.
|
-104.10M
est.
|
| EBIT |
-37.86M
est: -15.32M (-147.2%)
|
-41.42M
est: -17.30M (-139.4%)
|
-19.68M
est: -20.00M (+1.6%)
|
-30.00M
est.
|
-104.80M
est.
|
| Net Income |
-45.63M
est: -66.78M (+31.7%)
|
-66.10M
est: -53.85M (-22.8%)
|
-17.90M
est: -14.58M (-22.8%)
|
-10.35M
est.
|
21.63M
est.
|
| SGA |
42.19M
est: 40.34M (+4.6%)
|
29.71M
est: 45.56M (-34.8%)
|
20.03M
est: 52.67M (-62.0%)
|
79.00M
est.
|
275.99M
est.
|
| EPS |
-53.29
est: -42.60 (-25.1%)
|
-51.65
est: -34.35 (-50.4%)
|
-11.42
est: -9.30 (-22.8%)
|
-6.60
est.
|
13.80
est.
|
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-10.50M
OE per share TTM
-6.99
Owner's Yield
-760,233.75%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
170.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
22
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | George J. Schultze | 7.15M | 24.10% | 7.15M | — | 7.15M | — | IN | USA | 2020-12-28 | ↗ |
| 2 | Schultze Special Purpose Acquisition Sponsor, LLC | 7.15M | 24.10% | 7.15M | — | 7.15M | — | OO | Delaware | 2020-12-28 | ↗ |
| 3 | Andrew J. M. Spokes | 2.48M | 9.90% | — | 2.48M | — | 2.48M | IN | United States | 2020-12-31 | ↗ |
| 4 | David T. Kim | 2.48M | 9.90% | — | 2.48M | — | 2.48M | IN | United States | 2020-12-31 | ↗ |
| 5 | Farallon Capital Management, L.L.C. | 2.48M | 9.90% | — | 2.48M | — | 2.48M | OO | United States | 2020-12-31 | ↗ |
| 6 | John R. Warren | 2.48M | 9.90% | — | 2.48M | — | 2.48M | IN | United States | 2020-12-31 | ↗ |
| 7 | Mark C. Wehrly | 2.48M | 9.90% | — | 2.48M | — | 2.48M | IN | United States | 2020-12-31 | ↗ |
| 8 | Michael B. Fisch | 2.48M | 9.90% | — | 2.48M | — | 2.48M | IN | United States | 2020-12-31 | ↗ |
| 9 | Michael G. Linn | 2.48M | 9.90% | — | 2.48M | — | 2.48M | IN | United States | 2020-12-31 | ↗ |
| 10 | Neem Holdings, LLC | 2.48M | 9.90% | — | 2.48M | — | 2.48M | OO | United States | 2020-12-31 | ↗ |
| 11 | Philip D. Dreyfuss | 2.48M | 9.90% | — | 2.48M | — | 2.48M | IN | United States | 2020-12-31 | ↗ |
| 12 | Rajiv A. Patel | 2.48M | 9.90% | — | 2.48M | — | 2.48M | IN | United States | 2020-12-31 | ↗ |
| 13 | Richard B. Fried | 2.48M | 9.90% | — | 2.48M | — | 2.48M | IN | United States | 2020-12-31 | ↗ |
| 14 | Thomas G. Roberts, Jr. | 2.48M | 9.90% | — | 2.48M | — | 2.48M | IN | United States | 2020-12-31 | ↗ |
| 15 | William Seybold | 2.48M | 9.90% | — | 2.48M | — | 2.48M | IN | United States | 2020-12-31 | ↗ |
| 16 | Kyle Detwiler | 2.17M | 8.70% | 1.93M | 236.2K | 1.93M | — | HC, IN | United States | 2020-12-28 | ↗ |
| 17 | ETF Managers Group LLC | 949.3K | 3.54% | 949.3K | — | 949.3K | — | IA | Delaware | 2022-02-14 | ↗ |
| 18 | Sliver Swan, LLC | 236.2K | 1.00% | — | 236.2K | — | — | CO | Delaware | 2020-12-28 | ↗ |
| 19 | Antonio Costa | 149.3K | 8.50% | — | 149.3K | — | 10.00 | IN, OO | Brazil | 2024-05-15 | ↗ |
| 20 | B.Side Wealth Management Gestão de Recursos Ltda. | 149.3K | 8.50% | — | 149.3K | — | 10.00 | IA, OO | Brazil | 2024-05-15 | ↗ |
| 21 | Martim Prado Mattos | 149.3K | 8.50% | — | 149.3K | — | 10.00 | IN, OO | Brazil | 2024-05-15 | ↗ |
| 22 | Privado Investimento no Exterior | 149.3K | 8.50% | — | 149.3K | — | 10.00 | IV | Brazil | 2024-05-15 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 1 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Amplify Seymour Cannabis ETF CNBS | 0.00% | — | 1.09% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Ratio by volume
0.00
Bearish
Buys
0
Sells
3
Shares acquired
—
Shares disposed
2.1K
Cash buys
—
Cash sales
3.00
Net activity
-2,103
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-05-16 | BCM Investimentos Fundo de Investimento Multimercado Credito Privado Investimento no Exterior | 10% Owner | — | D | Common Shares, without par value | 0 | 0.00 | — | 322,234 | — | ↗ |
| 2024-03-08 | Hague Henry R III | Officer | S-Sale | D | Common shares | 170 | 3.31 | 562.84 | 11,951 | — | ↗ |
| 2024-02-27 | Hague Henry R III | Officer | S-Sale | D | Common shares | 411 | 3.95 | 1.6K | 12,121 | — | ↗ |
| 2024-01-19 | Wilches Julian | Officer | S-Sale | D | Common shares | 131 | 2.88 | 377.80 | 7,408 | — | ↗ |
| 2024-01-19 | Fajardo Andres | Director / Officer | S-Sale | D | Common shares | 1,561 | 2.88 | 4.5K | 21,795 | — | ↗ |
| 2023-12-20 | Wilches Julian | Officer | S-Sale | D | Common shares | 135 | 2.04 | 274.95 | 7,539 | — | ↗ |
| 2023-12-20 | Fajardo Andres | Director / Officer | S-Sale | D | Common shares | 177 | 2.04 | 360.50 | 23,356 | — | ↗ |
| 2023-07-18 | Wilches Julian | Officer | S-Sale | D | Common shares | 813 | 0.22 | 174.96 | 230,205 | — | ↗ |
| 2023-07-18 | Hague Henry R III | Officer | S-Sale | D | Common shares | 1,560 | 0.22 | 335.71 | 375,948 | — | ↗ |
| 2023-07-18 | Fajardo Andres | Director / Officer | S-Sale | D | Common shares | 2,938 | 0.22 | 632.26 | 705,996 | — | ↗ |
| 2023-06-29 | Muecke William | Director | S-Sale | D | Common shares | 251 | 0.21 | 51.66 | 110,257 | — | ↗ |
| 2023-06-29 | Julien Gary M | Director | S-Sale | D | Common shares | 251 | 0.21 | 51.66 | 122,025 | — | ↗ |
| 2023-05-31 | Wilches Julian | Officer | A-Award | A | Common shares | 183,000 | 0.00 | — | 231,018 | — | ↗ |
| 2023-05-31 | Schultze George J | Director | A-Award | A | Common shares | 40,000 | 0.00 | — | 115,276 | — | ↗ |
| 2023-05-31 | Muecke William | Director | A-Award | A | Common shares | 40,000 | 0.00 | — | 110,508 | — | ↗ |
| 2023-05-31 | Julien Gary M | Director | A-Award | A | Common shares | 40,000 | 0.00 | — | 122,276 | — | ↗ |
| 2023-05-31 | Hague Henry R III | Officer | A-Award | A | Common shares | 183,000 | 0.00 | — | 377,508 | — | ↗ |
| 2023-05-31 | Fajardo Andres | Director / Officer | A-Award | A | Common shares | 183,000 | 0.00 | — | 708,934 | — | ↗ |
| 2023-05-31 | DEMARSE ELISABETH H | Director | A-Award | A | Common shares | 40,000 | 0.00 | — | 122,276 | — | ↗ |
| 2023-03-03 | Hague Henry R III | Officer | S-Sale | D | Common shares | 5,678 | 0.37 | 2.1K | 194,508 | — | ↗ |
| 2023-02-24 | Hague Henry R III | Officer | S-Sale | D | Common shares | 9,018 | 0.42 | 3.8K | 200,186 | — | ↗ |
| 2023-02-22 | Hague Henry R III | Officer | S-Sale | D | Common shares | 9,728 | 0.44 | 4.3K | 209,204 | — | ↗ |
| 2023-01-17 | Wilches Julian | Officer | S-Sale | D | Common shares | 4,557 | 0.40 | 1.8K | 48,018 | — | ↗ |
| 2023-01-17 | Fajardo Andres | Officer | S-Sale | D | Common shares | 57,669 | 0.40 | 23.1K | 525,934 | — | ↗ |
| 2022-12-20 | Wilches Julian | Officer | S-Sale | D | Common shares | 3,829 | 0.34 | 1.3K | 52,575 | — | ↗ |
| 2022-12-20 | Fajardo Andres | Officer | S-Sale | D | Common shares | 5,133 | 0.34 | 1.7K | 583,603 | — | ↗ |
| 2022-07-06 | Wilches Julian | Officer | S-Sale | D | Common shares | 288 | 1.03 | 296.64 | 56,404 | — | ↗ |
| 2022-07-06 | Kastin David | Officer | S-Sale | D | Common shares | 565 | 1.03 | 581.95 | 172,151 | — | ↗ |
| 2022-07-06 | Hague Henry R III | Officer | S-Sale | D | Common shares | 598 | 1.03 | 615.94 | 218,932 | — | ↗ |
| 2022-07-06 | Fajardo Andres | Officer | S-Sale | D | Common shares | 1,170 | 1.03 | 1.2K | 588,736 | — | ↗ |
| 2022-06-24 | Schultze George J | Director | A-Award | A | Common shares | 68,807 | 0.00 | — | 75,276 | — | ↗ |
| 2022-06-24 | Muecke William | Director | A-Award | A | Common shares | 68,807 | 0.00 | — | 70,508 | — | ↗ |
| 2022-06-24 | Julien Gary M | Director | A-Award | A | Common shares | 68,807 | 0.00 | — | 82,276 | — | ↗ |
| 2022-06-24 | DEMARSE ELISABETH H | Director | A-Award | A | Common shares | 68,807 | 0.00 | — | 82,276 | — | ↗ |
| 2022-03-25 | Muecke William | Director | A-Award | A | Common shares | 1,701 | 0.00 | — | 1,701 | — | ↗ |
| 2022-03-03 | Kastin David | Officer | S-Sale | D | Common shares | 2,364 | 1.00 | 2.4K | 172,716 | — | ↗ |
| 2022-03-03 | Hague Henry R III | Officer | S-Sale | D | Common shares | 4,981 | 1.00 | 5.0K | 219,530 | — | ↗ |
| 2022-02-02 | Schultze Special Purpose Acquisition Sponsor, LLC | 10% Owner | J-Other | D | Warrants | 4,900,000 | 11.50 | 56.35M | 0 | — | ↗ |
| 2022-02-02 | Schultze George J | Director | A-Award | A | Common shares | 6,469 | 0.00 | — | 6,469 | — | ↗ |
| 2022-01-14 | Wilches Julian | Officer | A-Award | A | Common shares | 20,147 | 0.00 | — | 56,692 | — | ↗ |
| 2022-01-14 | Kastin David | Officer | A-Award | A | Common shares | 115,436 | 0.00 | — | 130,080 | — | ↗ |
| 2022-01-14 | Hague Henry R III | Officer | A-Award | A | Common shares | 144,926 | 0.00 | — | 224,511 | — | ↗ |
| 2022-01-14 | Fajardo Andres | Director / Officer | A-Award | A | Common shares | 520,000 | 0.00 | — | 589,906 | — | ↗ |
| 2022-01-14 | Detwiler Kyle | Director / Officer | A-Award | A | Common shares | 500,000 | 0.00 | — | 2,652,771 | — | ↗ |
| 2021-12-30 | Wilches Julian | Officer | S-Sale | D | Common shares | 3,316 | 3.20 | 10.6K | 36,545 | — | ↗ |
| 2021-12-30 | Kastin David | Officer | S-Sale | D | Common shares | 1,677 | 3.20 | 5.4K | 14,644 | — | ↗ |
| 2021-12-30 | Fajardo Andres | Director / Officer | S-Sale | D | Common shares | 4,472 | 3.20 | 14.3K | 69,906 | — | ↗ |
| 2021-12-30 | Detwiler Kyle | Director / Officer | S-Sale | D | Common shares | 46,390 | 0.00 | — | 2,152,771 | — | ↗ |
| 2021-07-01 | Wilches Julian | Officer | A-Award | A | Common shares | 6,528 | 0.00 | — | 39,861 | — | ↗ |
| 2021-07-01 | Kastin David | Officer | A-Award | A | Common shares | 16,321 | 0.00 | — | 16,321 | — | ↗ |
| 2021-07-01 | Hague Henry R III | Officer | A-Award | A | Restricted Share Units | 19,585 | 0.00 | — | 19,585 | — | ↗ |
| 2021-07-01 | Fajardo Andres | Director / Officer | A-Award | A | Common shares | 29,378 | 0.00 | — | 74,378 | — | ↗ |
| 2021-07-01 | Detwiler Kyle | Director / Officer | A-Award | A | Common shares | 29,378 | 0.00 | — | 2,199,161 | — | ↗ |
| 2021-06-29 | Julien Gary M | Director | A-Award | A | Common shares | 6,469 | 0.00 | — | 13,469 | — | ↗ |
| 2021-06-29 | Deffarges Etienne H. | Director | A-Award | A | Common shares | 6,469 | 0.00 | — | 13,469 | — | ↗ |
| 2021-06-29 | DEMARSE ELISABETH H | Director | A-Award | A | Common shares | 6,469 | 0.00 | — | 13,469 | — | ↗ |
| 2021-06-02 | Kastin David | Officer | — | D | Restricted Share Units | 0 | 0.00 | — | 25,000 | — | ↗ |
| 2021-03-16 | Wilches Julian | Officer | A-Award | A | Common shares | 33,333 | 0.00 | — | 33,333 | — | ↗ |
| 2021-03-16 | Fajardo Andres | Director / Officer | M-Exempt | D | Restricted Share Units | 45,000 | 0.00 | — | 0 | — | ↗ |
| 2021-03-16 | Detwiler Kyle | Director / Officer | A-Award | A | Common shares | 45,000 | 0.00 | — | 2,169,783 | — | ↗ |
| 2021-03-02 | Wilches Julian | Officer | A-Award | A | Restricted Share Units | 33,334 | 0.00 | — | 33,334 | — | ↗ |
| 2021-03-02 | Hague Henry R III | Officer | A-Award | A | Common shares | 60,000 | 0.00 | — | 60,000 | — | ↗ |
| 2021-03-02 | Fajardo Andres | Director / Officer | A-Award | A | Restricted Share Units | 45,000 | 0.00 | — | 45,000 | — | ↗ |
| 2021-03-02 | Detwiler Kyle | Director / Officer | A-Award | A | Common shares | 200,000 | 0.00 | — | 2,124,783 | — | ↗ |
| 2021-02-26 | Julien Gary M | Director | A-Award | A | Common shares | 7,000 | 0.00 | — | 7,000 | — | ↗ |
| 2021-02-26 | Deffarges Etienne H. | Director | A-Award | A | Common shares | 7,000 | 0.00 | — | 7,000 | — | ↗ |
| 2021-02-26 | DEMARSE ELISABETH H | Director | A-Award | A | Common shares | 7,000 | 0.00 | — | 7,000 | — | ↗ |
| 2021-02-22 | Hague Henry R III | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-01-17 | Schultze Special Purpose Acquisition Sponsor, LLC | 10% Owner | — | D | Warrants | 4,900,000 | 11.50 | 56.35M | 0 | — | ↗ |
| 2021-01-17 | Schultze George J | 10% Owner | — | I | Warrants | 4,900,000 | 11.50 | 56.35M | 0 | — | ↗ |
| 2020-12-18 | Wilches Julian | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-12-18 | Schultze Special Purpose Acquisition Sponsor, LLC | 10% Owner | — | D | Common shares | 0 | 0.00 | — | 2,281,036 | — | ↗ |
| 2020-12-18 | Schultze George J | 10% Owner | — | I | Common shares | 0 | 0.00 | — | 2,281,036 | — | ↗ |
| 2020-12-18 | Pandey Amit | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-12-18 | Julien Gary M | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-12-18 | Fajardo Andres | Director / Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-12-18 | Detwiler Kyle | Director / Officer | A-Award | A | Stock Option (right to buy) | 18,703 | 10.00 | 187.0K | 18,703 | — | ↗ |
| 2020-12-18 | Deffarges Etienne H. | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-12-18 | DEMARSE ELISABETH H | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-66.5K
Shares Outstanding
1.75M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Henry R. Hague | Chief Financial Officer | 311.0K | male |
| Andres Fajardo | Co-Founder, Chief Executive Officer & Director | 232.0K | male |
| Julian Wilches | Chief Regulatory Officer | 202.5K | male |
| Caroline Kliess | Managing Director of Germany | — | female |
| Gustavo Escobar | Chief Operating Officer | — | male |
| Jackie Keshner | Investor Relations Executive | — | female |
| Marta Pinto Leite | General Counsel & Corporate Secretary | — | female |
| Andrew Miller | Head of Business Development | — | male |
| Camilo Bohorquez | Head of Colombia | — | male |
ESG Rating
ESG Score History DRUG MANUFACTURERS - SPECIALTY & GENERIC
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for CLVR
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
